{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 172,
  "pageCount": 239,
  "prevPage": 171,
  "nextPage": 173,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a direct quote from a KOL to undermine the company's growth thesis.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/172",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-172",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "PDN wouldn't be a Nevro-driven market. If the numbers increase, you will probably see a distribution relatively equally over all the manufacturers and perhaps down the road, perhaps a little bit more for Abbott.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-662790edcff0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "The Nevro consultant’s/speaker’s point on PDN label exclusivity – that even if Nevro were to get “approval” for PDN, Medicare and others would apply it to all other stimulators – was reinforced by another KOL who remains a moderate Nevro user. He stated that “PDN wouldn’t be a Nevro-driven market” and that it wouldn’t alter Nevro’s sales much, adding that insurers simply do not monitor or care which stimulator doctors use for which indication. He stated that insurers only care “once in a 100” times.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ffa21f5-c97b-4fbb-a0a0-bb9373810235",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.88,
        "x": 0.06,
        "y": 0.35
      },
      "kind": "quote",
      "text": "“PDN wouldn’t be a Nevro-driven market. If the numbers increase, you will probably see a distribution relatively equally over all the manufacturers and perhaps down the road, perhaps a little bit more for Abbott. It's not necessarily a uniquely Nevro type of thing. I don't think all of a sudden it's going to dramatically change Nevro's numbers. The way the game works is that if company A gets FDA approval for indication X, the insurance companies do not really ask which device you're using, so you can technically use another device for an indication approved by Nevro. Very rarely will an insurer ask which device you're using. I've only seen that once in a 100.” - KOL and high volume implanter, moderate Nevro user",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44875f89-38f0-43c1-8937-7dff303ddf46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "PDN wouldn't be a Nevro-driven market. If the numbers increase, you will probably see a distribution relatively equally over all the manufacturers and perhaps down the road, perhaps a little bit more for Abbott. It's not necessarily a uniquely Nevro type of thing. I don't think all of a sudden it's going to dramatically change Nevro's numbers. The way the game works is that if company A gets FDA approval for indication X, the insurance companies do not really ask which device you're using, so you can technically use another device for an indication approved by Nevro. Very rarely will an insurer ask which device you're using. I've only seen that once in a 100. — KOL and high volume implanter, moderate Nevro user",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-69098318651d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23a1a116-75d4-4827-8326-d76b8eaf029b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "11. TAM expansion and growth from painful diabetic neuropathy (PDN) and other new indications are a mirage",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9106390-a065-4b08-a29e-b27d24461a0d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "977f8b7f-8828-45bd-94f7-3ce43c1c3321",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "e38e3f7a-5ef4-43ad-bd19-80953daccb55",
      "evidence": "Uses expert testimony to contradict company growth claims.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}